PHX - PharmX Technologies

Description
Corum Group Limited is an Australia-based company. The Company is engaged in the operation of a retail technology business providing point-of-sale software, pharmaceutical dispensing software, computer hardware and support services to the pharmacy industry. The Company operates in three segments: Healthcare-the Corum Health Services business, which is a provider of dispense and point of sale software applications, hardware and support services to Australian pharmacies through its controlled entities, Pharmasol Pty Limited and Amfac Pty Limited; Transaction Processing, which offers individuals and businesses the opportunity to effect payment of their rent, utilities, local government fees and commercial obligations via electronic methodologies through its controlled entity, Corum eCommerce Pty Limited, and Training, which is a registered training organization, providing training services to the real estate industry through its controlled entity, Corum Training Pty Limited.

Interesting move today, after the recent Quarterly (nice cash figures)

Someone took an interest with 200000 stocks

No other news yet.

Not much interest here in this boring little IT company which seems to have overcome its problems. Not often that you you see comments in a Chairman's address suchs as:

..................the Group has generated significant
cash from existing operating activities which has been utilised to:
• repay borrowings of $6,900,000;
• pay interest totalling $1,650,000; and
• settle legal actions which amounted to $2,500,000.

As at today Corum has settled all legal actions, the Group is
debt free, all assets are unencumbered, and tangible assets now
exceed total liabilities.

Accordingly Directors advise that they are of the opinion that up
to 50% of future cash surpluses, which are not able to be utilised
to expand the Company’s operations, should be distributed to
Shareholders; the format of such a distribution is yet to be
determined.

Click to expand...

http://www.asx.com.au/asxpdf/20121121/pdf/42bbmhw9z90l38.pdf

It has been good to me over the past 6 months and I may top up again if it holds its break through $.155

Cheers
Country Lad

Country Lad said:

Not much interest here in this boring little IT company which seems to have overcome its problems. Not often that you you see comments in a Chairman's address suchs as:

It has been good to me over the past 6 months and I may top up again if it holds its break through $.155

Cheers
Country Lad

Click to expand...

Definitely back from the brink. Got some at an average of 7.6c so pretty happy with the performance. The announcement of dividend resumption is definitely a positive.

COO makes software for pharmacies. Speaking to a pharmacist friend - they basically don't really think about switching or anything like that. It's an expense they just pay and get on with their business. However, the key threat is that independent pharmacies seem to be on the decline - so if the market overall shrinks, COO would feel the impact.

Any one with any current thoughts on this one?

Seems to have dropped 25% without any real cause. Not much real prospect of any decent growth without something new happening, revenues remain constant and costs grow slowly higher but with the sharp decline in share price it is aproaching a PE of 5 which doesnt seem to be justified.....

clowboy said:

Any one with any current thoughts on this one?

Click to expand...

Sorry, I haven't looked at this one since the stop at 20 saw me out of it.


Cheers
Country Lad

clowboy said:

Any one with any current thoughts on this one?

Seems to have dropped 25% without any real cause. Not much real prospect of any decent growth without something new happening, revenues remain constant and costs grow slowly higher but with the sharp decline in share price it is aproaching a PE of 5 which doesnt seem to be justified.....

Click to expand...

The latest 4c showed that it generated $1.5m op cashflow for the quarter which is pretty consistent with YTD. They can probably generate $6m in cash every year before tax. With heaps of accumulated loss they won't have a tax bill (nor franking credits) for some time.

$6m cashflow is ~2.5cps. If they start paying 1.5-1.8c out as dividend (leaving them ~$2m for investing), it is not a stretch for them to trade at <7% yield, which equates to a share price of ~21c+.

Well, I looked at the thread a few weeks ago, but never posted... (Have mentioned COO elsewhere),
it was on my buy list, but I never quite got there... further to run? Dunno, have missed seeing order flow.
Either way, volume has been thin and spread is probably an issue as well. Those characteristics can and do quickly change though. More watching required for me.

Financials

• Total group revenue for the quarter(1) of $3.3m up 7% on pcp.
• Health Services revenue of $3.0m for the quarter(1), up 11% on pcp, primarily attributable to PharmX.
• Real Estate eCommerce decline in line with expectations with revenue for the quarter of $0.3m(1), down 20% on pcp.
• Closing cash balance as of 26 October 2021 of $7.5m (up 16% since 30 June 2021)

part of a much bigger update

DYOR

i hold COO and have a buy order in @ 6c in the market

i don't expect anything sensational (this has been a laggard for years for me ) but MAYBE it still has a little wag left in the tail

i would have put it in the 'dogs of December ' but it hasn't paid a div. since February 2015 so GG might think i am stretching his patience on that one

Symbion & ProPharma sign long term PharmX agreement – Additional Information Corum Group Limited (ASX:COO) - As announced earlier today, the leading wholesalers in Australia and New Zealand, Symbion and ProPharma have signed a long term deal for their wholesale businesses to continue to utilise the PharmX platform. The agreement which is effective from 1 January 2022 is for an initial term of 3 years with a rolling term for a further 2 years.
This contract renewal provides security of revenue from one of PharmX’s largest customers for the next 3-5 years and further strengthens the relationship between the businesses following on from the long term deal signed with TerryWhite Chemart announced in December 2021. Symbion and ProPharma currently contribute approximately 5% of total group revenue. Key terms of the contract The original agreement between PharmX and Symbion was first entered into in 2007 with 4 further letters of extension signed in the years up to 2018.
In that year, the contract was amended to include the ProPharma business in New Zealand. Under the terms of the Agreement, PharmX grants access to its platform for the electronic ordering of products by customers of Symbion.
Revenue is predominantly derived from monthly access charges per customer.
In relation to the key terms of the contract: liability and indemnity under the agreement is limited and there are mutual confidentiality provisions and information security obligations.
The termination clause permits termination for a material breach of the agreement or an Insolvency Event. Symbion is an integral part of the Australian healthcare system, providing wholesale services to over 4,000 pharmacy customers.
ProPharma is the only national pharmaceutical wholesaler in New Zealand.

DYOR

i hold COO and have a buy order in @ 5.8c in the market

looks like i will miss out , but you never know with these minnows

On October 4th, 2023, Corum Group Limited (COO) changed its name and ASX code to PharmX Technologies Limited (PHX).

Pharmx Technologies partners with Toniq to expand pharmacy software solutions in New Zealand
Pharmx now has 99% pharmacy reach across both Australia and New Zealand through a new strategic partnership with Toniq.
Pharmx Technologies Ltd (ASX: PHX) (Pharmx Technologies) today confirms a strategic
partnership with Toniq, the leading provider of pharmacy point-of-sale (POS) and dispensary
software solutions in New Zealand.
A member of the global healthcare technology group Clanwilliam, Toniq supports over 900
pharmacies and holds an estimated 85% market share in New Zealand’s pharmacy POS and
dispensary software sector.
Under the terms of the partnership, pharmacies within the Toniq POS network can migrate to the
Pharmx electronic data interchange - Pharmx Gateway - enabling real-time inventory ordering,
automated eInvoice generation and seamless supplier connectivity.
This partnership also offers Pharmx’s supplier customers a broader reach and more
opportunities to scale business growth across the ANZ region. For pharmacies, it provides
unrivalled efficiency and a focus on patient centricity by erasing time-consuming administrative
tasks linked to ordering and inventory management.
The Pharmx Gateway was built to streamline pharmacy operations by enhancing ordering
accuracy, reducing manual processes, and providing real-time inventory management.
Additional features such as automated e-invoice generation and direct supplier connectivity will
further minimise administrative burdens and optimise transaction workflows across the supply
chain.
Pharmx Gateway has demonstrated to save pharmacies an average of 40 minutes per order,
which annually can equate to one full-time employee. Pharmx Gateway also saved suppliers
approximately 15 minutes in processing time per order.
Across Pharmx’s strategic partnerships in New Zealand, Pharmx now has 99% coverage of the
NZ pharmacy sector. This increases our regional coverage to 99% across both Australia
and New Zealand. Whilst at this time the Company cannot accurately determine the material
financial impact of the strategic partnership with Toniq, this milestone reinforces our position as the leading pharmacy ordering network and strengthens our commitment to redefining industry connectivity.
Tom Culver, CEO of Pharmx Technologies commented,
"The Pharmx Gateway has revolutionised pharmacy supply chains in our existing markets, and
we are thrilled to bring this innovation to New Zealand through a strategic partnership with a
like-minded industry leader.
Together, Pharmx and Toniq are on a mission to empower pharmacists, freeing them from the
burdens of manual ordering and inventory management so they can focus on what truly
matters—patient care. By extending Pharmx’s services to new regions, we are enabling more
pharmacies and suppliers to embrace a connected, technology-driven, data-led approach to
inventory and order management.”
The combination of Toniq’s Pharmacy Retail footprint and existing workflows with Pharmx’s
superior technology stack is expected to deliver a large efficiency boost throughout the NZ
pharmaceutical supply chain.
Toniq commented,
“ Toniq is a premier provider of pharmacy management software in New Zealand, dedicated to
enhancing the efficiency and effectiveness of pharmacy operations. With a focus on
innovation and user-friendly solutions, Toniq offers a comprehensive suite of tools designed to
streamline various aspects of pharmacy management.
We are thrilled to announce a ground-breaking partnership between Toniq and PharmX, aimed
at revolutionising the pharmacy ordering experience. This collaboration brings together
Toniq’s innovative pharmacy management software and PharmX’s advanced ordering
solutions to create a seamless, efficient, and user-friendly system for pharmacies.
Together, Toniq and PharmX are committed to delivering cutting-edge solutions that empower
pharmacies to provide the best possible care to their patients.”


This announcement has been authorised for release by the Board of Pharmx Technologies
Limited.

i hold PHX ( bought as COO ) this hasn't been one of my success stories ... but maybe ..